Trade and other receivables and other current assets

12 Months Ended

Dec. 31, 2024

Trade and other receivables and other current assets

Trade and other receivables and other current assets

20. Trade and other receivables and other current assets


		December 31,
	2024		2023

	(Euro, in thousands)
Trade receivables	€	32,471	€	17,494
Current contingent consideration receivable		4,742		—
Prepayments		103		738
Other receivables		10,160		10,217
Trade and other receivables		47,476		28,449
Accrued income		835		508
Deferred charges		30,214		14,632
Other current assets		31,049		15,140
Total trade and other receivables & other current assets	€	78,525	€	43,589

The carrying value of trade and other receivables & other current assets approximate their fair value.

The increase in deferred charges mainly related to $15.0 million in R&D funding paid to Adaptimmune which will gradually be released in R&D expenses over the R&D period.

We refer to note 5 for more information on the current contingent consideration receivable.

On December 31, 2024, we had a provision for expected credit losses of €9.6 million, for two disputed invoices. We did not account for a provision for expected credit losses relating to all our other trade and other receivables since we don’t have a history of credit losses and we are not aware of any forward-looking information that could materially influence the credit risk.